Spring til hovednavigation Spring til søgning Spring til hovedindhold

A polygenic risk score for multiple myeloma risk prediction

  • Federico Canzian
  • , Chiara Piredda
  • , Angelica Macauda
  • , Daria Zawirska
  • , Niels Frost Andersen
  • , Arnon Nagler
  • , Jan Maciej Zaucha
  • , Grzegorz Mazur
  • , Charles Dumontet
  • , Marzena Wątek
  • , Krzysztof Jamroziak
  • , Juan Sainz
  • , Judit Várkonyi
  • , Aleksandra Butrym
  • , Katia Beider
  • , Niels Abildgaard
  • , Fabienne Lesueur
  • , Marek Dudziński
  • , Annette Juul Vangsted
  • , Matteo Pelosini
  • Edyta Subocz, Mario Petrini, Gabriele Buda, Małgorzata Raźny, Federica Gemignani, Herlander Marques, Enrico Orciuolo, Katalin Kadar, Artur Jurczyszyn, Agnieszka Druzd-Sitek, Ulla Vogel, Vibeke Andersen, Rui Manuel Reis, Anna Suska, Hervé Avet-Loiseau, Marcin Kruszewski, Waldemar Tomczak, Marcin Rymko, Stephane Minvielle, Daniele Campa
  • Department of Biology, University of Pisa, Pisa, Italy.
  • Department of Hematology, University Hospital of Cracow, Cracow, Poland.
  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Department of Hematology, Sea Hospital, Gdynia, Poland.
  • Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
  • Cancer Research Center of Lyon/Hospices Civils de Lyon, Lyon, France.
  • Hematology Clinic, Holycross Cancer Center, Kielce, Poland.
  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
  • Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
  • Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Institut Curie, PSL Research University, Mines ParisTech Inserm, U900, Paris, France.
  • Hematology Department, Teaching Hospital No 1, Rzeszów, Poland.
  • Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Denmark.
  • Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
  • Department of Haematology, Military Institute of Medicine, Warsaw, Poland.
  • Department of Hematology, Rydygier Specialistic Hospital, Cracow, Poland.
  • Life and Health Sciences Research Institute (ICVS), School of Health Sciences/Molecular Oncology Research Center, University of Minho, Braga, Portugal.
  • Department of Hematology, Jagiellonian University Medical College, Cracow, Poland.
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Molecular Oncology Research Center, Barretos Cancer Hospital, S.Paulo, Brazil.
  • Unité de Génomique du Myélome, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.
  • Department of Hematology, University Hospital, Bydgoszcz, Poland.
  • Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
  • Department of Hematology, N. Copernicus Town Hospital, Torun, Poland.
  • CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
  • Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • University of Granada
  • University of Minho
  • Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

There is overwhelming epidemiologic evidence that the risk of multiple myeloma (MM) has a solid genetic background. Genome-wide association studies (GWAS) have identified 23 risk loci that contribute to the genetic susceptibility of MM, but have low individual penetrance. Combining the SNPs in a polygenic risk score (PRS) is a possible approach to improve their usefulness. Using 2361 MM cases and 1415 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium, we computed a weighted and an unweighted PRS. We observed associations with MM risk with OR = 3.44, 95% CI 2.53-4.69, p = 3.55 × 10-15 for the highest vs. lowest quintile of the weighted score, and OR = 3.18, 95% CI 2.1 = 34-4.33, p = 1.62 × 10-13 for the highest vs. lowest quintile of the unweighted score. We found a convincing association of a PRS generated with 23 SNPs and risk of MM. Our work provides additional validation of previously discovered MM risk variants and of their combination into a PRS, which is a first step towards the use of genetics for risk stratification in the general population.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Human Genetics
Vol/bind30
Udgave nummer4
Sider (fra-til)474-479
ISSN1018-4813
DOI
StatusUdgivet - apr. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'A polygenic risk score for multiple myeloma risk prediction'. Sammen danner de et unikt fingeraftryk.

Citationsformater